# Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
Canonical URL: https://biopharmsignal.com/news/SRRK/scholar-rock-reports-first-quarter-2026-financial-results-and-recent-business-highlights
Ticker: SRRK
Company: Scholar Rock
Source: Scholar Rock
Published: 2026-05-07 11:00 EST
Original Source URL: https://investors.scholarrock.com
## Summary

FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of

## Article Body
FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of
## Recent Company News
- 2026-05-26 13:30 EST — [Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Scholar Rock
- 2026-05-20 12:00 EST — [Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-2026-jefferies-global-healthcare-conference) — Source: Scholar Rock
- 2026-05-07 11:00 EST — [Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/SRRK/scholar-rock-reports-first-quarter-2026-financial-results-and-recent-business-highlights) — Source: Scholar Rock
- 2026-04-29 12:00 EST — [Scholar Rock to Present at the BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-bofa-securities-2026-health-care-conference) — Source: Scholar Rock
- 2026-04-17 20:15 EST — [Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Scholar Rock
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)